DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 966 filers reported holding DANAHER CORPORATION in Q1 2015. The put-call ratio across all filers is 0.54 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $459,729 | +3.4% | 1,853 | 0.0% | 0.04% | +8.3% |
Q2 2023 | $444,720 | -4.8% | 1,853 | 0.0% | 0.04% | -7.7% |
Q1 2023 | $467,030 | -5.0% | 1,853 | 0.0% | 0.04% | -11.4% |
Q4 2022 | $491,823 | +4.6% | 1,853 | +1.8% | 0.04% | -4.3% |
Q3 2022 | $470,000 | +2.0% | 1,820 | 0.0% | 0.05% | +9.5% |
Q2 2022 | $461,000 | -13.7% | 1,820 | 0.0% | 0.04% | 0.0% |
Q1 2022 | $534,000 | -30.8% | 1,820 | -22.5% | 0.04% | -22.2% |
Q4 2021 | $772,000 | +39.4% | 2,347 | +29.0% | 0.05% | +20.0% |
Q3 2021 | $554,000 | +14.7% | 1,820 | +1.1% | 0.04% | +18.4% |
Q2 2021 | $483,000 | +19.3% | 1,800 | 0.0% | 0.04% | 0.0% |
Q1 2021 | $405,000 | +1.2% | 1,800 | 0.0% | 0.04% | -9.5% |
Q4 2020 | $400,000 | +3.1% | 1,800 | 0.0% | 0.04% | -8.7% |
Q3 2020 | $388,000 | +22.0% | 1,800 | 0.0% | 0.05% | +12.2% |
Q2 2020 | $318,000 | +27.7% | 1,800 | 0.0% | 0.04% | +10.8% |
Q1 2020 | $249,000 | -9.8% | 1,800 | 0.0% | 0.04% | +27.6% |
Q4 2019 | $276,000 | +6.2% | 1,800 | 0.0% | 0.03% | 0.0% |
Q3 2019 | $260,000 | +1.2% | 1,800 | 0.0% | 0.03% | -3.3% |
Q2 2019 | $257,000 | +8.0% | 1,800 | 0.0% | 0.03% | +7.1% |
Q1 2019 | $238,000 | +28.0% | 1,800 | 0.0% | 0.03% | +16.7% |
Q4 2018 | $186,000 | -5.1% | 1,800 | 0.0% | 0.02% | +9.1% |
Q3 2018 | $196,000 | +4.3% | 1,800 | -5.5% | 0.02% | 0.0% |
Q2 2018 | $188,000 | +0.5% | 1,905 | 0.0% | 0.02% | 0.0% |
Q1 2018 | $187,000 | +5.6% | 1,905 | 0.0% | 0.02% | +4.8% |
Q4 2017 | $177,000 | +8.6% | 1,905 | 0.0% | 0.02% | 0.0% |
Q3 2017 | $163,000 | +1.2% | 1,905 | 0.0% | 0.02% | -4.5% |
Q2 2017 | $161,000 | -1.2% | 1,905 | 0.0% | 0.02% | 0.0% |
Q1 2017 | $163,000 | +10.1% | 1,905 | 0.0% | 0.02% | 0.0% |
Q4 2016 | $148,000 | +1750.0% | 1,905 | +1714.3% | 0.02% | +2100.0% |
Q3 2016 | $8,000 | -27.3% | 105 | 0.0% | 0.00% | -50.0% |
Q2 2016 | $11,000 | +10.0% | 105 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $10,000 | 0.0% | 105 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $10,000 | +11.1% | 105 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $9,000 | 0.0% | 105 | 0.0% | 0.00% | 0.0% |
Q2 2015 | $9,000 | 0.0% | 105 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $9,000 | 0.0% | 105 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $9,000 | +12.5% | 105 | 0.0% | 0.00% | 0.0% |
Q3 2014 | $8,000 | 0.0% | 105 | 0.0% | 0.00% | 0.0% |
Q2 2014 | $8,000 | 0.0% | 105 | 0.0% | 0.00% | 0.0% |
Q1 2014 | $8,000 | – | 105 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |